Tenon Medical, Inc.

Tenon Medical, Inc.

Tenon Medical, Inc. is a publicly traded medical device company specializing in the sacroiliac (SI) joint fusion market. The firm was founded in 2017 and is headquartered in Los Gatos, California. Its primary product, the Catamaran SI Joint Fusion System, received 510(k) clearance from the FDA in December 2017 (per FDA database, 2017). The company targets orthopedic and neurosurgeons who treat lower back pain caused by SI joint dysfunction. The firm's strategy centers on commercializing the Catamaran device through direct sales to hospitals and ambulatory surgery centers. Key competitors include SI-BONE, Zyga Technology, and other device makers in the SI joint fusion space. Tenon Medical's market focus is North America, with particular emphasis on the United States. The company reported revenue growth in recent fiscal periods but has not disclosed profitability (per SEC filings, 2025). Tenon Medical operates as a publicly traded entity with shares listed on the Nasdaq under the ticker TNON. The firm has approximately 15–30 employees based on public disclosures and industry norms. The company maintains a single headquarters in California with no known additional offices. No philanthropic foundation or adjacent investment vehicles have been publicly associated with Tenon Medical. The structural differentiator for Tenon Medical is its status as a publicly traded single-product medical device company rather than a family office or private investment firm. The firm's narrow focus on the SI joint fusion market, with only one cleared product, creates a concentrated risk profile that differs from diversified medical device conglomerates. The company's governance follows public company norms with a board of directors and SEC compliance obligations.